{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:55:20Z","timestamp":1790952920846,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic syndrome (MetS) is highly prevalent among individuals with affective disorders and contributes substantially to premature cardiovascular morbidity and mortality. However, the relative contribution of demographic characteristics, psychiatric diagnosis, and psychotropic medication to metabolic risk remains incompletely understood. This study investigated the prevalence of MetS and its associated demographic, clinical, and treatment-related factors in hospitalized patients with major depressive disorder (MDD) and bipolar disorder (BD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted in 502 adult psychiatric inpatients diagnosed with MDD or BD. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. Demographic characteristics, psychiatric diagnosis, metabolic parameters, and psychotropic medication were analyzed. Independent correlates of MetS were identified using multivariable binary logistic regression, excluding variables constituting the diagnostic criteria for MetS to avoid circularity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Metabolic syndrome was identified in 25.4% of the study population. Patients with MetS were significantly older and more frequently female than those without MetS (both p &amp;lt; 0.001). Although bipolar disorder was not significantly associated with MetS in univariate analyses, it became independently associated with MetS after multivariable adjustment (adjusted OR 1.77, 95% CI 1.04\u20133.02; p = 0.037), together with increasing age (adjusted OR 1.06 per year, 95% CI 1.04\u20131.08; p &amp;lt; 0.001) and female sex (adjusted OR 1.87, 95% CI 1.18\u20132.98; p = 0.008). Current psychotropic medication, assessed at the time of hospital admission, was not independently associated with MetS after adjustment for demographic and clinical characteristics. These findings should not be interpreted as evidence against the established long-term metabolic effects of psychotropic medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metabolic syndrome represents a common medical comorbidity among hospitalized patients with affective disorders. Increasing age, female sex, and bipolar disorder were independently associated with MetS, whereas current psychotropic medication, assessed cross-sectionally at hospital admission, was not independently associated with metabolic syndrome after adjustment. This finding should be interpreted in the context of unavailable information regarding cumulative treatment exposure, duration, dosage, and previous medication history. These findings support routine metabolic monitoring as an integral component of psychiatric care, particularly among older adults, women, and patients with bipolar disorder.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1796346","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:27:31Z","timestamp":1790951251000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic syndrome in patients diagnosed with affective disorders: a cross-sectional study among inpatients from two Cluj-Napoca psychiatry clinics"],"prefix":"10.3389","volume":"17","author":[{"given":"Patricea Iulia","family":"Huluba","sequence":"first","affiliation":[{"name":"Department of Neurosciences, University of Medicine & Pharmacy \u201cIuliu Ha\u0163ieganu\u201d","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin C.","family":"Lung","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of Medicine & Pharmacy \u201cIuliu Ha\u0163ieganu\u201d","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Crecan-Suciu","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of Medicine & Pharmacy \u201cIuliu Ha\u0163ieganu\u201d","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona L.","family":"Paunescu","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of Medicine & Pharmacy \u201cIuliu Ha\u0163ieganu\u201d","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca C.","family":"Bibolar","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of Medicine & Pharmacy \u201cIuliu Ha\u0163ieganu\u201d","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Miclutia","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of Medicine & Pharmacy \u201cIuliu Ha\u0163ieganu\u201d","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global epidemic of the metabolic syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"B3","volume-title":"The IDF Consensus Worldwide Definition of the Metabolic Syndrome","year":"2006"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2055","article-title":"Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies","volume":"35","author":"Pan","year":"2012","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large-scale meta-analysis","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2016.07.003","article-title":"Depression and cardiovascular disease: epidemiological evidence on their linking mechanisms","volume":"74","author":"Penninx","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12050620","article-title":"Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators","volume":"170","author":"Vancampfort","year":"2013","journal-title":"Am J Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jad.2013.01.014","article-title":"A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise","volume":"148","author":"Lopresti","year":"2013","journal-title":"J Affect Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.573479","article-title":"Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness","volume":"11","author":"Mazereel","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2015.02.010","article-title":"Metabolic syndrome in patients with bipolar disorder: comparison with major depressive disorder and non-psychiatric controls","volume":"78","author":"Silarova","year":"2015","journal-title":"J Psychosom Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0000000000001293","article-title":"Gender differences in the prevalence and clinical correlates of metabolic syndrome in first-episode and drug-na\u00efve patients with major depressive disorder","volume":"86","author":"Zhang","year":"2024","journal-title":"Psychosom Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1038\/s41598-021-81653-2","article-title":"The prevalence and related factors of metabolic syndrome in outpatients with first-episode drug-na\u00efve major depression comorbid with anxiety","volume":"11","author":"Zhong","year":"2021","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1590\/1516-4446-2017-2328","article-title":"Metabolic syndrome and psychiatric disorders: a population-based study","volume":"41","author":"Moreira","year":"2019","journal-title":"Braz J Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2165\/11533280-000000000-00000","article-title":"The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications","volume":"24","author":"McIntyre","year":"2010","journal-title":"CNS Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.2","article-title":"Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies","volume":"67","author":"Luppino","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2018.07.004","article-title":"EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association, supported by the International Organization of Physical Therapists in Mental Health","volume":"54","author":"Stubbs","year":"2018","journal-title":"Eur Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1210\/er.2008-0024","article-title":"The metabolic syndrome","volume":"29","author":"Cornier","year":"2008","journal-title":"Endocr Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.717824","article-title":"Metabolic syndrome impairs executive function in bipolar disorder","volume":"15","author":"Dalkner","year":"2021","journal-title":"Front Neurosci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20458","article-title":"Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis","volume":"16","author":"Vancampfort","year":"2017","journal-title":"World Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1275177","article-title":"The association between neuroendocrine\/glucose metabolism and clinical outcomes and disease course in different clinical states of bipolar disorders","volume":"15","author":"Xu","year":"2024","journal-title":"Front Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41398-024-02921-z","article-title":"Inflammatory mediators in major depression and bipolar disorder","volume":"14","author":"Poletti","year":"2024","journal-title":"Transl Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1358578","article-title":"Sleep, mood disorders, and the ketogenic diet: potential therapeutic targets for bipolar disorder and schizophrenia","volume":"15","author":"Choi","year":"2024","journal-title":"Front Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jpsychires.2014.04.017","article-title":"Inflammatory mediators of cognitive impairment in bipolar disorder","volume":"56","author":"Bauer","year":"2014","journal-title":"J Psychiatr Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/npp.2016.199","article-title":"Inflammation, glutamate, and glia: a trio of trouble in mood disorders","volume":"42","author":"Haroon","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.24869\/psyd.2023.210","article-title":"May PPAR\u03b3 be significant in bipolar disorder only in the presence of metabolic syndrome","volume":"35","author":"Kok Kendirlioglu","year":"2023","journal-title":"Psychiatr Danub"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2015.09.006","article-title":"Bipolar disorder and inflammation","volume":"39","author":"Rosenblat","year":"2016","journal-title":"Psychiatr Clin North Am"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1338544","article-title":"Integrating mitoepigenetics into research in mood disorders: a state-of-the-art review","volume":"15","author":"Ceylan","year":"2024","journal-title":"Front Physiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105766","article-title":"Inflammatory and oxidative stress biomarkers in children and adolescents with bipolar disorder: a systematic review and meta-analysis","volume":"163","author":"Munkholm","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13165","article-title":"Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: a critical multidisciplinary literature review and agenda for future research from the ISBD Task Force on Chronobiology","volume":"24","author":"McCarthy","year":"2022","journal-title":"Bipolar Disord"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.11.012","article-title":"Does metabolic syndrome or its component factors alter the course of bipolar disorder? A systematic review","volume":"132","author":"Crespo","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2024.100754","article-title":"Circulating levels of brain-derived neurotrophic factor (BDNF) in patients with bipolar disorders may be influenced by mitochondrial dysfunction, inflammation, and history of childhood trauma","volume":"16","author":"Saitoh","year":"2024","journal-title":"J Affect Disord Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.20230009","article-title":"The CANMAT and ISBD guidelines for the treatment of bipolar disorder: summary and a 2023 update of evidence","volume":"21","author":"Keramatian","year":"2023","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"B40","volume-title":"Bipolar disorder: assessment and management (NG185\/CG185)","year":"2014"},{"key":"B41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments and International Society for Bipolar Disorders 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"B42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20773","article-title":"A meta-review of lifestyle psychiatry: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders","volume":"19","author":"Firth","year":"2020","journal-title":"World Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13643-022-02067-3","article-title":"Systematic review of lifestyle interventions to improve weight, physical activity and diet among people with a mental health condition","volume":"11","author":"Bradley","year":"2022","journal-title":"Syst Rev"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1796346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:27:32Z","timestamp":1790951252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1796346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":45,"alternative-id":["10.3389\/fpsyt.2026.1796346"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1796346","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1796346"}}